These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20595032)

  • 1. Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: a target for anti-malarial chemotherapy.
    Keough DT; Hocková D; Krecmerová M; Cesnek M; Holý A; Naesens L; Brereton IM; Winzor DJ; de Jersey J; Guddat LW
    Mol Biochem Parasitol; 2010 Oct; 173(2):165-9. PubMed ID: 20595032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases.
    Hocková D; Keough DT; Janeba Z; Wang TH; de Jersey J; Guddat LW
    J Med Chem; 2012 Jul; 55(13):6209-23. PubMed ID: 22725979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.
    Česnek M; Hocková D; Holý A; Dračínský M; Baszczyňski O; Jersey Jd; Keough DT; Guddat LW
    Bioorg Med Chem; 2012 Jan; 20(2):1076-89. PubMed ID: 22178188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.
    Krečmerová M; Dračínský M; Hocková D; Holý A; Keough DT; Guddat LW
    Bioorg Med Chem; 2012 Feb; 20(3):1222-30. PubMed ID: 22249123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agents.
    Keough DT; Hocková D; Janeba Z; Wang TH; Naesens L; Edstein MD; Chavchich M; Guddat LW
    J Med Chem; 2015 Jan; 58(2):827-46. PubMed ID: 25494538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unusual substrate specificity of a chimeric hypoxanthine-guanine phosphoribosyltransferase containing segments from the Plasmodium falciparum and human enzymes.
    Sujay Subbayya IN; Sukumaran S; Shivashankar K; Balaram H
    Biochem Biophys Res Commun; 2000 Jun; 272(2):596-602. PubMed ID: 10833458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
    Hocková D; Holý A; Masojídková M; Keough DT; de Jersey J; Guddat LW
    Bioorg Med Chem; 2009 Sep; 17(17):6218-32. PubMed ID: 19666228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
    Keough DT; Hocková D; Holý A; Naesens LM; Skinner-Adams TS; Jersey Jd; Guddat LW
    J Med Chem; 2009 Jul; 52(14):4391-9. PubMed ID: 19527031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acyclic Nucleoside Phosphonates Containing 9-Deazahypoxanthine and a Five-Membered Heterocycle as Selective Inhibitors of Plasmodial 6-Oxopurine Phosphoribosyltransferases.
    Kaiser MM; Baszczyňski O; Hocková D; Poštová-Slavětínská L; Dračínský M; Keough DT; Guddat LW; Janeba Z
    ChemMedChem; 2017 Jul; 12(14):1133-1141. PubMed ID: 28628279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme.
    Keough DT; Ng AL; Winzor DJ; Emmerson BT; de Jersey J
    Mol Biochem Parasitol; 1999 Jan; 98(1):29-41. PubMed ID: 10029307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acidic residues in the purine binding site govern the 6-oxopurine specificity of the Leishmania donovani xanthine phosphoribosyltransferase.
    Ullman B; Cyr N; Choi K; Jardim A
    Int J Biochem Cell Biol; 2010 Feb; 42(2):253-62. PubMed ID: 19861168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altering the purine specificity of hypoxanthine-guanine-xanthine phosphoribosyltransferase from Tritrichomonas foetus by structure-based point mutations in the enzyme protein.
    Munagala NR; Wang CC
    Biochemistry; 1998 Nov; 37(47):16612-9. PubMed ID: 9843428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs.
    de Jersey J; Holý A; Hocková D; Naesens L; Keough DT; Guddat LW
    Curr Top Med Chem; 2011; 11(16):2085-102. PubMed ID: 21619515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activity.
    Keough DT; Špaček P; Hocková D; Tichý T; Vrbková S; Slavětínská L; Janeba Z; Naesens L; Edstein MD; Chavchich M; Wang TH; de Jersey J; Guddat LW
    J Med Chem; 2013 Mar; 56(6):2513-26. PubMed ID: 23448281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for multiple active states of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
    Sujay Subbayya IN; Balaram H
    Biochem Biophys Res Commun; 2000 Dec; 279(2):433-7. PubMed ID: 11118304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs.
    Špaček P; Keough DT; Chavchich M; Dračínský M; Janeba Z; Naesens L; Edstein MD; Guddat LW; Hocková D
    Bioorg Med Chem; 2017 Aug; 25(15):4008-4030. PubMed ID: 28601510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferase. Stability studies on the product-activated enzyme.
    Raman J; Ashok CS; Subbayya SI; Anand RP; Selvi ST; Balaram H
    FEBS J; 2005 Apr; 272(8):1900-11. PubMed ID: 15819884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.
    Baszczyňski O; Hocková D; Janeba Z; Holý A; Jansa P; Dračínský M; Keough DT; Guddat LW
    Eur J Med Chem; 2013 Sep; 67():81-9. PubMed ID: 23850568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a bacterial screen for novel hypoxanthine-guanine phosphoribosyltransferase substrates.
    Shivashankar K; Subbayya IN; Balaram H
    J Mol Microbiol Biotechnol; 2001 Oct; 3(4):557-62. PubMed ID: 11545274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Plasmodium vivax Hypoxanthine-Guanine Phosphoribosyltransferase Inhibitors as Potential Antimalarial Therapeutics.
    Keough DT; Rejman D; Pohl R; Zborníková E; Hocková D; Croll T; Edstein MD; Birrell GW; Chavchich M; Naesens LMJ; Pierens GK; Brereton IM; Guddat LW
    ACS Chem Biol; 2018 Jan; 13(1):82-90. PubMed ID: 29161011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.